Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB

Informations projet

UshTher

N° de convention de subvention: 754848

DOI

10.3030/754848

Projet clôturé

Date de signature de la CE 27 Novembre 2017

Date de début 1 Janvier 2018

Date de fin 30 Juin 2023

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 5 998 515,75

Contribution de l’UE

€ 5 998 515,75

Coordonné par

FONDAZIONE TELETHON ETS
Italy

Periodic Reporting for period 4 - UshTher (Clinical trial of gene therapy with dual AAV vectors for retinitis pigmentosa in patients with Usher syndrome type IB)

Période du rapport: 2022-01-01 au 2023-06-30

Résumé du contexte et des objectifs généraux du projet

The project aimed to revolutionize the treatment of Usher Syndrome Type IB (USHIB), a challenging eye condition. The primary objectives included the production of dual AAV vectors, designed to be thoroughly tested in labs and then in clinical trials, ensuring their safety and effectiveness. The team also conducted an in-depth study with patients suffering from USHIB, aiming to deeply understand their condition and how it progresses over time. A significant part of this project was to navigate the complex process of gaining approval for a phase I/II clinical trial. The goal of this trial was ambitious yet vital – to rigorously test the safety and effectiveness of these innovative vectors in treating this challenging eye condition.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

In this ambitious project, we successfully generated of dual AAV vectors, a significant step forward in the treatment of eye conditions. These vectors were meticulously prepared for both lab-based and clinical research. Importantly, long-term studies confirmed that these vectors remained stable and effective over extended periods, a crucial aspect for any medical treatment.
In terms of safety and how these vectors behave in the body, studies conducted on non-human primates provided valuable insights. The vectors predominantly targeted the visual pathways, a promising sign for their potential use in treating eye disorders. These studies also carefully examined the safety of these vectors, observing changes in eye structure and function depending on the dosage, which is a vital step in ensuring patient safety in any new medical treatment.
A key element of the project was the comprehensive study of patients with Usher Syndrome Type IB (USHIB). This study provided crucial baseline data and a deeper understanding of how this eye condition progresses, information that is essential for developing effective treatments.
The journey towards the clinical trial phase was marked by detailed regulatory preparations. The submission of necessary documents led to a conditional approval for a crucial phase I/II clinical trial. This phase highlighted the need for further clarification on the quality of the Drug Product, an important step in ensuring the highest standards for patient safety and treatment efficacy.
Despite some delays due to this conditional approval, the project's momentum continued. The team focused on enhancing the quality systems and obtaining authorization for using the viral vector, laying a solid foundation for the upcoming clinical trial. This preparatory phase is crucial for the smooth and successful execution of the trial, ensuring that every aspect of the treatment is thoroughly vetted and ready for clinical evaluation.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

This project marked a significant leap forward in the field of gene therapy, particularly in the treatment of Usher Syndrome Type IB (USHIB). Through meticulous research, the project shed light on the potential of dual AAV vectors. These vectors were rigorously tested for stability, safety, and their ability to target specific areas in pre-clinical models, laying a solid foundation for their future use in human treatments. Additionally, the project's in-depth study of USHIB patients was a crucial endeavor, offering rich insights into the progression of this condition and bolstering our understanding significantly.
The potential impacts of this project are far-reaching. For those affected by USHIB, a rare genetic disorder, these findings bring a beacon of hope. The possibility of a new, effective treatment method could greatly enhance their quality of life. Beyond USHIB, this project's advancements hold significant implications for the healthcare sector at large. The knowledge and techniques developed here could be applied to a range of genetic disorders, potentially transforming treatment approaches in the wider realm of medical research.
Despite its successes, the project encountered several obstacles, particularly in securing regulatory approval for the clinical trial, which led to some delays. These hurdles were not insurmountable; through additional testing and necessary adjustments, the project met the stringent quality standards required for clinical applications.
In conclusion, this project not only advanced our understanding of dual AAV vectors in the context of USHIB but also overcame substantial scientific and regulatory challenges. The completion of both pre-clinical studies and the natural history study of USHIB patients, coupled with the groundwork laid for the upcoming clinical trial, represent significant strides toward harnessing the therapeutic potential of these vectors. While there were delays, the project paves an optimistic path for future clinical applications, not just in the treatment of USHIB but possibly for other genetic disorders as well.

UshTher logo